Balance of glutathione system activity in ascitic ovarian tumor under the experimental conditions
DOI:
https://doi.org/10.12775/JEHS.2024.70.58778Keywords
ascitic ovarian tumor, glutathione system, reductase, peroxidase, control pathologyAbstract
The article presents the experimental results of the investigation the glutathione system activity in rats simulated ovarian ascites tumor. It was found that the glutathione system in the form of glutathione reductase and glutathione peroxidase is inactivated after 2 months, but at 4 months of study the activity of these enzymatic systems increases. Treatment with gammaglobulins gives a certain therapeutic effect due to a change in the activity of the studied enzymes involved in redox intracellular reactions. It was established that for 2 months activation of glutathione peroxidase with parallel inhibition of glutathione reductase. However, for 4 months the activity changed in the opposite direction.
References
1. Ershova L. A., Savytskyi I. V., Mykhailuk M. M., Gerasymenko T. V., Savytskyi V. I., Badiuk N.S. Studing of the glutathione system activity in ascitic ovarian tumor under experimental conditions with gammaglobulins treatment / PharmacologyOnLine; Archives - 2021 - vol. 2 – 812-818.
2. Cytokines as Prognostic Biomarkers of Epithelial Ovarian Cancer (EOC): A Systematic Review and Meta-Analysis / M. N. Fahmi, H. Pradjatmo, I. Astuti, R. D. Nindrea. Asian Pacific Journal of Cancer Prevention. 2021. Vol. 22 (2). P. 315-323. doi: 10.31557/APJCP.2021.22.2.315
3. Development and validation a simple model for identify malignant ascites / Y.-Y. Guo, X.-L. Peng, N. Zhan et al. International Journal of Medical Sciences. 2021. Vol. 18 (9). P. 1966-1974. doi: 10.7150/ijms.53743.
4. Diagnostic efficacy of ascites cell block for ovarian clear cell carcinoma / H. Iwahashi, M. Miyamoto, S. Minabe et al. Diagnostic Cytopathology. 2021. Vol. 49 (6). P. 735-742. doi.org/10.1002/dc.24734
5. Kipps E., Tan D. S. P., Kaye S. B. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nature Reviews Cancer. 2013. Vol. 13 (4). P. 273-282. doi: 10.1038/nrc3432.
6. Ovarian Cancer Statistics / L. A. Torre, B. Trabert, C. E. De Santis et al. Cancer J. Clin. 2018. Vol. 68. P. 284–296. doi: 10.3322/caac.21456.
7. Ovarian Cancer-Associated Mesothelial Cells: Transdifferentiation to Minions of Cancer and Orchestrate Developing Peritoneal Dissemination / K. Mogi, M. Yoshihara, S. Iyoshi et al. Cancers. 2021. Vol. 13 (6). P. 1362. doi.org/10.3390/cancers13061352.
8. Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer / Q. Quan, S. Zhou, Y. Lio et al. The Journal of Obstetrics and Gynaecology Research. 2021. Vol. 47 (4). P. 1527-1535. doi.org/10.1111/jog.14682
9. The untapped potential of ascites in ovarian cancer research and treatment / C. E. Ford, B. Werner, N. F. Hacker, K. Warton. British Journal of Cancer. 2020. Vol. 123 (1). P. 9-16.
10. Understanding the effect of mechanical forces on ovarian cancer progression / A. Martinez, M. Buckley, C. B. Scalise et al. Gynecologic Oncology. 2021. Vol. 162 (1). P. 154-162. doi.org/10.1016/j.ygyno.2021.04.003.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 V. Sarakhan
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 61
Number of citations: 0
